{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=warfarin+sodium&page=2", "query": { "intervention": "warfarin sodium", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=warfarin+sodium&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T03:21:16.383Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01597310", "title": "Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Warfarin", "type": "DRUG" }, { "name": "Dexpramipexole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Knopp Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 15, "start_date": "2012-05", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2014-11-25", "last_synced_at": "2026-09-29T03:21:16.383Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01597310" }, { "nct_id": "NCT00027066", "title": "Warfarin Versus Aspirin Recurrent Stroke Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stroke" ], "interventions": [ { "name": "Active Aspirin", "type": "DRUG" }, { "name": "Active Warfarin", "type": "DRUG" }, { "name": "Aspirin placebo", "type": "DRUG" }, { "name": "Warfarin placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 2206, "start_date": "1993-06", "completion_date": "2001-11", "has_results": false, "last_update_posted_date": "2011-06-17", "last_synced_at": "2026-09-29T03:21:16.383Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027066" }, { "nct_id": "NCT03271450", "title": "The DARE Warfarin CER Study", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Deep Venous Thrombosis", "Pulmonary Embolism" ], "interventions": [ { "name": "Dabigatran: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Dabigatran: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Dabigatran: extended treatment (e.g at least 270 days)", "type": "DRUG" }, { "name": "Apixaban: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Apixaban: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Apixaban: extended treatment (e.g at least 270 days)", "type": "DRUG" }, { "name": "Rivaroxaban: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Rivaroxaban: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Rivaroxaban: extended treatment (e.g at least 270 days)", "type": "DRUG" }, { "name": "Edoxaban: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Edoxaban: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Edoxaban: extended treatment (e.g at least 270 days)", "type": "DRUG" }, { "name": "Warfarin: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Warfarin: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Warfarin: extended treatment (e.g at least 270 days)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 416000, "start_date": "2017-07-01", "completion_date": "2021-10-30", "has_results": false, "last_update_posted_date": "2021-06-23", "last_synced_at": "2026-09-29T03:21:16.383Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03271450" }, { "nct_id": "NCT00927862", "title": "Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Thromboembolism" ], "interventions": [ { "name": "IWPC adapted genotype-guided dosing algorithm for warfarin", "type": "GENETIC" }, { "name": "Modified IWPC genetic-guided warfarin dosing algorithm", "type": "GENETIC" }, { "name": "Standard of care treatment", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Intermountain Health Care, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2415, "start_date": "2008-08", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2012-09-25", "last_synced_at": "2026-09-29T03:21:16.383Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00927862" }, { "nct_id": "NCT00001713", "title": "Treatment for Blood Clots in the Veins of the Legs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Embolism", "Thrombophlebitis" ], "interventions": [ { "name": "Recombinant Tissue Plasminogen Activator", "type": "DRUG" }, { "name": "Heparin", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20, "start_date": "1998-02", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-29T03:21:16.383Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001713" }, { "nct_id": "NCT00559988", "title": "Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atrial Fibrillation", "Atrial Flutter", "Stroke", "Embolism, Systemic Arterial", "Major Bleeding" ], "interventions": [ { "name": "Home Monitoring Guided OAC", "type": "DRUG" }, { "name": "Physician-Directed OAC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biotronik, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2718, "start_date": "2008-02", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-09-29T03:21:16.383Z", "location_count": 73, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00559988" }, { "nct_id": "NCT01391962", "title": "Sunitinib or Cediranib for Alveolar Soft Part Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma, Alveolar Soft Part" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Prochlorperazine", "type": "OTHER" }, { "name": "Promethazine", "type": "OTHER" }, { "name": "Benzodiazepine", "type": "OTHER" }, { "name": "Filgrastim", "type": "OTHER" }, { "name": "Sargramostim", "type": "OTHER" }, { "name": "Lomotil", "type": "OTHER" }, { "name": "Loperamide", "type": "OTHER" }, { "name": "Vitamin B6", "type": "OTHER" }, { "name": "Aquaphor", "type": "OTHER" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Levothyroxine", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "16 Years to 120 Years" }, "enrollment_count": 34, "start_date": "2011-07-18", "completion_date": "2026-01-16", "has_results": true, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-09-29T03:21:16.383Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01391962" }, { "nct_id": "NCT04735523", "title": "Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Dabigatran", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 5350, "start_date": "2020-09-22", "completion_date": "2021-02-18", "has_results": false, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-09-29T03:21:16.383Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04735523" }, { "nct_id": "NCT06055920", "title": "The PEERLESS II Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pulmonary Embolism" ], "interventions": [ { "name": "FlowTriever System", "type": "DEVICE" }, { "name": "Anticoagulation Agents", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Inari Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1200, "start_date": "2023-11-17", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-29T03:21:16.383Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Pasadena", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06055920" }, { "nct_id": "NCT03702582", "title": "Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Stroke", "Bleeding" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2019-04-30", "completion_date": "2023-10-01", "has_results": true, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-09-29T03:21:16.383Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03702582" } ] }